Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

JPMorgan Chase & Co. (JPM) Rises As Revenues, Earnings Beat Estimates

Page 1 of 2

JPMorgan Chase & Co. (NYSE:JPM) this morning reported an increase in earnings in the second quarter to $6.29 billion, or $1.54 per share, up from $5.98 billion, or $1.46 a share, in the prior-year quarter. Income gains were largely driven by the Corporate and Investment Bank division, which earned $2.3 billion compared to $2.1 billion year-over-year. Commercial Banking income on the other hand fell by $152 million year-over-year, while Consumer and Community Banking income posted a slight gain. Wall Street was expecting an EPS of $1.44. However, the financial giant also reported that revenue fell to $24.53 billion, down from $25.34 billion in the same quarter last year, though this still beat estimates as well, with analysts expecting $24.49 billion. Tangible book value per share showed gains of 7% year-over-year, to $46.13. Shares of America’s largest bank by assets rose to a high of $68.90 in pre-market trading, up by about 1%, though the gains have since been clawed back to only slightly above level. Shares of JPMorgan Chase & Co. hit their all-time high in the second quarter at $69.75 per share. Year-to-date, the stock has risen by 7.76%.

JP Morgan Chase JPM Office

pcruciatti /


The increase in profits for JPMorgan Chase & Co. (NYSE:JPM) emulates the increase in hedge fund interest in recent months. Total holdings held by the funds tracked by Insider Monkey increased by 8.12% during the first quarter to $7.64 billion, even though the stock slumped by 3.2% in the first quarter. The smart money was vindicated for their faith and investment dollars, however, in the second quarter, as the stock jumped by 11.15%. By the end of March, a total of 95 of the hedge funds tracked by Insider Monkey were bullish in this stock, up from 92 at the end of the fourth quarter.

Hedge funds and other big money managers tend to have the largest amounts of their capital invested in large and mega-cap stocks like JPMorgan Chase & Co. because these companies allow for much greater capital allocation. That’s why if we take a look at the most popular stocks among funds, we won’t find any mid- or small-cap stocks there. However, our backtests of hedge funds’ equity portfolios between 1999 and 2012 revealed that the 50 most popular stocks among hedge funds underperformed the market by seven basis points per month, showing that their most popular picks and the ones that received the bulk of their capital were not actually their best picks. On the other hand, their top small-cap picks performed considerably better, outperforming the market by 95 basis points per month. This was confirmed through backtesting and in forward tests of our small-cap strategy since August 2012. The strategy, which involves imitating the 15 most popular small-cap picks among hedge funds has provided gains of more than 135%, beating the broader market by over 80 percentage points through the end of April (see the details).

Another area Insider Monkey tracks is insider trades. These transactions can tell people whether certain key insiders of companies are betting on their own company’s stocks. For JPMorgan Chase & Co., Director Michael Neal acquired 9,050 shares of the firm on January 15. The most recent sales by insiders was on April 15 when COO Matthew Zames sold 4,258 shares and General Counsel Stephen Cutler sold 18,617 shares.

Taking this into consideration, we’re going to take a look at the fresh smart money activity regarding JPMorgan Chase & Co.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!